IRX2 Antibody - middle region (ARP31580_P050)
- Known as:
- IRX2 Antibody - middle region (ARP31580_P050)
- Catalog number:
- arp31580_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- IRX2 Antibody - middle region (ARP31580_P050)
Related genes to: IRX2 Antibody - middle region (ARP31580_P050)
- Gene:
- C5orf38 NIH gene
- Name:
- chromosome 5 open reading frame 38
- Previous symbol:
- -
- Synonyms:
- CEI, IRX2NB
- Chromosome:
- 5p15.33
- Locus Type:
- gene with protein product
- Date approved:
- 2007-02-19
- Date modifiied:
- 2016-11-22
- Gene:
- IRX2 NIH gene
- Name:
- iroquois homeobox 2
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 5p15.33
- Locus Type:
- gene with protein product
- Date approved:
- 2001-07-20
- Date modifiied:
- 2015-08-25
Related products to: IRX2 Antibody - middle region (ARP31580_P050)
Related articles to: IRX2 Antibody - middle region (ARP31580_P050)
- Human induced pluripotent stem cells (hiPSCs) are useful tools for reproducing neural development . However, each hiPSC line has a different ability to differentiate into specific lineages, known as differentiation propensity, resulting in reduced reproducibility and increased time and funding requirements for research. To overcome this issue, we searched for predictive signatures of neural differentiation propensity of hiPSCs focusing on DNA methylation, which is the main modulator of cellular properties. - Source: PubMed
Publication date: 2022/12/01
Sekiya AsatoTakasawa KenArai YoshikazuHorike Shin-IchiAkutsu HidenoriUmezawa AkihiroNishino Koichiro - Eribulin, a natural product-based microtubule targeting agent with cytotoxic and noncytotoxic mechanisms, is FDA approved for certain patients with advanced breast cancer and liposarcoma. To investigate the feasibility of developing drug-specific predictive biomarkers, we quantified antiproliferative activities of eribulin versus paclitaxel and vinorelbine against 100 human cancer cell lines from the Cancer Cell Line Encyclopedia, and correlated results with publicly available databases to identify genes and pathways associated with eribulin response, either uniquely or shared with paclitaxel or vinorelbine. Mean expression ratios of 11,985 genes between the most and least sensitive cell line quartiles were sorted by -values and drug overlaps, yielding 52, 29 and 80 genes uniquely associated with eribulin, paclitaxel and vinorelbine, respectively. Further restriction to minimum 2-fold ratios followed by reintroducing data from the middle two quartiles identified 9 and 13 drug-specific unique fingerprint genes for eribulin and vinorelbine, respectively; surprisingly, no gene met all criteria for paclitaxel. Interactome and Reactome pathway analyses showed that unique fingerprint genes of both drugs were primarily associated with cellular signaling, not microtubule-related pathways, although considerable differences existed in individual pathways identified. Finally, four-gene (, , , ) and five-gene (, , , , ) multivariate regression models for eribulin and vinorelbine showed high statistical correlation with drug-specific responses across the 100 cell lines and accurately calculated predicted mean IC50s for the most and least sensitive cell line quartiles as surrogates for responders and nonresponders, respectively. Collectively, these results provide a foundation for developing drug-specific predictive biomarkers for eribulin and vinorelbine. - Source: PubMed
Publication date: 2022/09/19
Sachdev PallaviRonen RoyDutkowski JanuszLittlefield Bruce A